John Reynolds
Monash University
H-index: 42
Oceania-Australia
Top articles of John Reynolds
Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy
Blood Advances
2024/4/9
Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies
Blood Advances
2024/3/14
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)
Journal of Clinical Oncology
2024/3/1
Rethinking the transfusion pathway in myelodysplastic syndromes: Study protocol for a novel randomized feasibility n‐of‐1 trial of weekly‐interval red cell transfusion in …
Transfusion
2024/2
Circulating tumor DNA and bone marrow minimal residual disease negativity confers superior outcome for multiple myeloma patients
Haematologica
2024
Evaluation of Easym, a Clonotypic Mass Spectrometry Assay, and Euroflow Minimal Residual Disease Assessment in Multiple Myeloma
Blood
2023/11/28
An intervention to improve the self-efficacy of key workers to support parental wellbeing at an early childhood intervention service in Australia: a stepped wedged randomized …
Disability and Rehabilitation
2023/9/11
P-476 More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures: the MY-PROMPT …
Clinical Lymphoma Myeloma and Leukemia
2023/9/1
PB2698: MORE EFFICIENT DELIVERY OF HIGH-COST STANDARD-OF-CARE THERAPIES IN RELAPSED MULTIPLE MYELOMA USING REAL-TIME FEEDBACK OF PATIENT-REPORTED OUTCOME MEASURES: THE MY …
HemaSphere
2023/8/1
P365: SEQUENTIAL BLINATUMOMAB WITH REDUCED INTENSITY CHEMOTHERAPY FOR OLDER ADULTS WITH NEWLY DIAGNOSED PH-B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA–FINAL RESULTS OF THE ALLG …
HemaSphere
2023/8/1
A sequential cohort study evaluating single‐agent KappaMab and KappaMab combined with lenalidomide and low‐dose dexamethasone in relapsed and/or refractory kappa light chain …
British Journal of Haematology
2023/8
Response adaptive salvage with KTd and ASCT for functional high‐risk multiple myeloma—The Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial
British Journal of Haematology
2023/8
Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation
The Journal of invasive cardiology
2021/10/1
Circulating tumour DNA-based molecular response predicts treatment outcome in multiple myeloma
Cancer Research
2023/4/4
A structured, telephone-delivered intervention to reduce methamphetamine use: study protocol for a parallel-group randomised controlled trial
Trials
2023/3/29
Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma
Blood Cancer Journal
2023/2/13
Persisting Gaps in Optimal Care of Stage III Non-small Cell Lung Cancer: An Australian Patterns of Care Analysis
The Oncologist
2023/2/1
Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG
Blood
2023/12/7
Combining TNFR2-expressing tregs and IL-6 as superior diagnostic biomarkers for high-grade serous ovarian cancer masses
Cancers
2023/1/21
Cell Free MYC DNA Copy Number Identifies High-Risk Smouldering Myeloma and Newly Diagnosed Multiple Myeloma
Blood
2023/11/28
Co-Authors
